InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Image-Guided Drug Delivery Market Size, Share & Trends Analysis Report By Technology Type (Drug-Delivery Systems and Image-Guided Platforms), Application (Oncology, Neurology, and Others), End-use (Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes & Universities, and Contract Research Organizations (CROs)),-Market Outlook And Industry Analysis 2034″
Image-Guided Drug Delivery Market Size is valued at US$ 58.9 Mn in 2024 and is predicted to reach US$ 687.4 Mn by the year 2034 at an 28.1% CAGR during the forecast period for 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3211
Image-guided drug delivery (IGDD) is an emerging clinical approach that integrates targeted therapeutic administration with advanced imaging modalities to enhance treatment efficacy, safety, and precision. Utilizing imaging technologies such as computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), and ultrasound, clinicians can visualize organs and tissues in real time. This capability enables precise control over the delivery of medications to specific disease sites, including tumors or affected organs, while minimizing exposure to surrounding healthy tissues.
The image-guided drug delivery market is experiencing rapid growth, driven by technological advancements in medical imaging and an increasing demand for precision medicine. Furthermore, the rising prevalence of oncology and neurological disorders is fueling market expansion, supported by continuous improvements in MRI, CT, and PET technologies that enhance the accuracy and reliability of this targeted therapeutic approach.
List of Prominent Players in the Image-Guided Drug Delivery Market:
- ClearPoint Neuro, Inc.
- AiM Medical Robotics
- TriSalus Life Sciences
- RenovoRx Inc.
- Renishaw plc.
- Occam Design
- Infuseon Therapeutics Inc
- Neurochase
- GE HealthCare
- Koninklijke Philips N.V.
Read Overview Report- https://www.insightaceanalytic.com/report/image-guided-drug-delivery-market/3211
Market Dynamics:
Drivers:
The growth of the global image-guided drug delivery (IGDD) market is largely driven by continuous advancements in imaging technologies, including MRI, CT, PET, and ultrasound, which now offer improved spatial resolution and real-time visualization of drug distribution. These technological enhancements increase therapeutic efficacy, reduce off-target effects, and enable precise targeting of diseased tissues. The rising demand for personalized and minimally invasive therapies, particularly in oncology and neurology, further supports market expansion.
Additionally, the growing adoption of theranostic and precision medicine approaches, which integrate imaging diagnostics with treatment administration to tailor therapy to individual patient profiles, is a significant market driver. The increasing prevalence of chronic diseases such as cancer, Alzheimer’s, and cardiovascular disorders also fuels demand for efficient, targeted, and innovative treatment modalities.
Challenges:
Despite the market potential, several challenges may constrain the adoption of IGDD systems. The high cost of advanced imaging equipment and associated infrastructure poses a significant barrier, particularly in developing regions where financial constraints limit access to cutting-edge medical technology. Moreover, integrating imaging modalities with drug delivery systems presents technical complexities, requiring precise coordination between imaging and delivery platforms for accurate therapeutic administration. These technical challenges, combined with substantial initial investment costs, may restrict widespread market penetration.
Regional Trends:
In 2024, North America led the global IGDD market, supported by a robust healthcare infrastructure, extensive research and development initiatives, and the presence of prominent medical device manufacturers. Significant investments in technologies such as robotics, augmented reality, and artificial intelligence (AI) have enhanced the accuracy, effectiveness, and outcomes of image-guided treatments. The growing elderly population affected by chronic conditions such as cancer, cardiovascular, and musculoskeletal diseases in the United States further drives the adoption of IGDD solutions.
The Asia Pacific region is projected to witness rapid market growth due to expanding healthcare infrastructure, increasing investments in medical imaging technologies, and rising awareness of advanced treatment options. Countries including China, Japan, South Korea, and India are experiencing accelerated adoption of IGDD systems, driven by large patient populations and government initiatives promoting precision and minimally invasive therapies. The increasing prevalence of cancer and neurological disorders in the region further amplifies the demand for targeted treatment solutions. Collaborative efforts between local healthcare providers and global medical technology companies are also improving accessibility and reducing the cost of advanced IGDD devices in these markets.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3211
Recent Developments:
- August 2025: A significant milestone in clinical implementation was reached when ClearPoint Neuro, Inc. announced the first-ever commercial delivery of KEBILIDI (AADC deficient gene therapy) in the United States utilizing its FDA-approved SmartFlow Neuro Cannula.
- April 2025: Johns Hopkins Medicine began accepting patients with locally advanced pancreatic cancer (LAPC) into RenovoRx’s TIGeR-PaC study. By contrasting it with conventional intravenous chemotherapy, the trial assesses RenovoRx’s intra-arterial gemcitabine (IAG) delivery using the RenovoCath device. The trial is strengthened by this addition, which aims to reach complete enrollment by the end 2025.
- October 2023: The U.S. FDA has granted 510(k) approval to GE HealthCare’s Allia IGS Pulse system. The system supported complex cardiac operations on patients of various sizes thanks to a newly built imaging chain that provided high-quality imaging at optimal radiation doses. The company’s interventional portfolio is strengthened by this approval, which also helps to solidify its place in the market.
Segmentation of Image-Guided Drug Delivery Market-
By Technology Type-
- Drug-Delivery Systems
- Image-Guided Platforms
By Application-
- Oncology
- Neurology
- Others
By End-use-
- Hospitals
- Pharmaceutical & Biotechnology Companies
- Research Institutes & Universities
- Contract Research Organizations (CROs)
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
